X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
rheumatoid arthritis (11) 11
rheumatology (9) 9
patients (7) 7
biomarkers (6) 6
index medicus (6) 6
arthritis (5) 5
cytokines (5) 5
etanercept (5) 5
monoclonal antibodies (5) 5
infliximab (4) 4
tumor necrosis factor-α (4) 4
adalimumab (3) 3
confidence intervals (3) 3
proteins (3) 3
rheumatic diseases (3) 3
statistical analysis (3) 3
studies (3) 3
abridged index medicus (2) 2
ankylosing spondylitis (2) 2
biologic agents (2) 2
communication (2) 2
ct-p13 (2) 2
decision making (2) 2
disease (2) 2
disease-activity (2) 2
experience (2) 2
flare (2) 2
genetic variance (2) 2
genotype & phenotype (2) 2
golimumab (2) 2
health risk assessment (2) 2
humans (2) 2
interleukin 1 (2) 2
joint diseases (2) 2
leukocytes (2) 2
low disease activity (2) 2
low disease-activity (2) 2
marker (2) 2
medicine (2) 2
prediction of response (2) 2
quality of life (2) 2
regression analysis (2) 2
remission (2) 2
rheumatoid factor (2) 2
rheumatoid-arthritis (2) 2
serum biomarkers (2) 2
single-nucleotide polymorphism (2) 2
spondylitis (2) 2
survival (2) 2
tapering (2) 2
therapy (2) 2
1506 (1) 1
adalimumab plus methotrexate (1) 1
adjustment (1) 1
adolescent (1) 1
adsorption (1) 1
adult (1) 1
aged (1) 1
agents (1) 1
alpha (1) 1
amniotic-fluid (1) 1
analysis (1) 1
ankylosing-spondylitis (1) 1
antirheumatic agents - administration & dosage (1) 1
area under curve (1) 1
arthralgia (1) 1
arthritis, rheumatoid - blood (1) 1
arthritis, rheumatoid - drug therapy (1) 1
article (1) 1
bacterial (1) 1
bdmard (1) 1
bdmards (1) 1
bias (1) 1
binding (1) 1
biological products - administration & dosage (1) 1
biomarker (1) 1
biomarkers - blood (1) 1
biomass (1) 1
body weight (1) 1
c-reactive protein (1) 1
c-reactive protein - metabolism (1) 1
calprotectin (1) 1
care and treatment (1) 1
case-control studies (1) 1
cells (1) 1
chemical engineering (1) 1
chemical industry (1) 1
child (1) 1
child, preschool (1) 1
citrulline (1) 1
clinical remission (1) 1
clinical trials (1) 1
clinical-outcomes (1) 1
clinical-response (1) 1
cloning (1) 1
cohort (1) 1
composites (1) 1
construct (1) 1
cytomegalovirus (1) 1
damage (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


BMC Immunology, ISSN 1471-2172, 2014, Volume 15, Issue 1, pp. 55 - 55
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 03/2018, Volume 77, Issue Suppl 1, p. A46
IntroductionSince the introduction of biologics in the treatment of rheumatoid arthritis (RA) disease outcome improved. Still, about 40% of RA patients do not... 
Cytokines | Leukocytes (mononuclear) | Single-nucleotide polymorphism | Tumor necrosis factor-α | Gene expression | Proteins | Genetic variance | Genotype & phenotype | Etanercept | Rheumatoid arthritis | Interleukin 1 | Monoclonal antibodies | Protein expression | Genotypes
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 06/2016, Volume 75, Issue Suppl 2, pp. 232 - 233
BackgroundBetter prediction of treatment response to biologics in rheumatoid arthritis (RA) would contribute to optimal individualised treatment. Clinical data... 
Journal Article
Journal of Rheumatology, ISSN 0315-162X, 11/2018, Volume 45, Issue 11, pp. 1515 - 1521
Objective. To investigate predictors of flare in rheumatoid arthritis (RA) patients with low disease activity (LDA) and to evaluate the effect of flare on... 
RHEUMATOID ARTHRITIS | SERUM BIOMARKERS | FLARE | LOW DISEASE ACTIVITY | QUALITY OF LIFE | MULTIBIOMARKER DISEASE ACTIVITY SCORE | CONSTRUCT | FINGER JOINTS | BIOMARKER | MARKER | RHEUMATOLOGY | DAMAGE | SYNOVITIS | ULTRASOUND | COHORT | PROGRESSION | REMISSION
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 06/2015, Volume 74, Issue Suppl 2, pp. 657 - 658
BackgroundIL-32 is a cytokine that can be spliced into various isoforms with different potency and can induce pro-inflammatory cytokines like IL-6, IL-1β and... 
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 06/2017, Volume 76, Issue Suppl 2, p. 557
BackgroundIn blinded trials, transitioning from an innovator to a biosimilar has shown to be equivalent to maintenance on innovator biologic treatment in... 
Intravenous administration | Etanercept | Infliximab | Decision making | Rheumatic diseases | Clinical trials | Monoclonal antibodies | Remission | Tumor necrosis factor-α | Patients | Communication
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 06/2018, Volume 77, Issue Suppl 2, p. 608
BackgroundOpen-label mandatory transitioning to a biosimilar has no impact on disease activity in inflammatory rheumatic diseases.1 In light of shared... 
Pregnancy | Etanercept | Disease | Decision making | Rheumatic diseases | Arthritis | Malignancy | Patients | Communication
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 06/2016, Volume 75, Issue Suppl 2, pp. 1019 - 1019
BackgroundDisease activity guided tapering of tumor necrosis factor inhibitors (TNFi) has been shown to be feasible, safe and cost-effective in rheumatoid... 
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 06/2016, Volume 75, Issue Suppl 2, pp. 198 - 199
BackgroundTapering of biologics has been shown feasible, effective and safe in rheumatoid arthritis (RA) patients with stable low disease activity. Tapering of... 
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 06/2017, Volume 76, Issue Suppl 2, p. 519
BackgroundApproximately 60% of RA patients do not achieve good clinical response after 6 months of treatment with a TNF inhibitor (TNFi).1 To date, no... 
Biomarkers
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 06/2017, Volume 76, Issue Suppl 2, p. 526
BackgroundDose reduction and discontinuation of TNF inhibitors (TNFi) have been shown feasible in a large proportion of RA patients with low disease activity.1... 
Biomarkers
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 06/2017, Volume 76, Issue Suppl 2, p. 568
BackgroundAlthough anti-cyclic citrullinated peptide (anti-CCP) positivity is regarded as a strong prognostic factor for untreated RA outcome, the benefit of... 
Immunoglobulin M | Rheumatoid factor | Glucocorticoids | Tumor necrosis factor | Body weight | Rheumatology | Rituximab | Citrulline | Patients | Morbidity
Journal Article
Arthritis & Rheumatology, ISSN 2326-5191, 2018, Volume 70, Issue 9, pp. 1408 - 1418
Objective. To evaluate the effects of non-mandatory transitioning from the originator biologic drug etanercept (ETN) to its biosimilar, SB4, on drug survival... 
RHEUMATOID-ARTHRITIS | SELF-EFFICACY | NATIONWIDE NONMEDICAL SWITCH | INFLAMMATORY ARTHRITIS | EXPERIENCE | RHEUMATOLOGY | INFLIXIMAB | CT-P13 | EXPECTANCY | DISEASE-ACTIVITY | CLINICAL-OUTCOMES
Journal Article
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, ISSN 0392-856X, 05/2019, Volume 37, Issue 3, pp. 367 - 372
Objective To investigate ex-vivo drug-inhibited cytokine production before the start of a biological DMARD (bDMARD) as predictor of treatment response in... 
CELLS | ADALIMUMAB | bDMARD | biomarkers | GOLIMUMAB | prediction of response | cytokines | RHEUMATOLOGY | rheumatoid arthritis | DISEASE-ACTIVITY
Journal Article
Clinical and Experimental Rheumatology, ISSN 0392-856X, 01/2018, Volume 36, Issue 1, pp. 140 - 143
Objective. Clinical data suggest that the response of rheumatoid arthritis patients to treatment with golimumab is much lower among those who switched from... 
Golimumab | Treatment | Cytokines | Adalimumab | Rheumatoid arthritis | treatment | cytokines | RHEUMATOLOGY | rheumatoid arthritis | adalimumab | golimumab
Journal Article
RMD Open, ISSN 2056-5933, 04/2018, Volume 4, Issue 1, p. e000654
ObjectivesCalprotectin (S100A8/A9) has been correlated with disease activity in rheumatoid arthritis (RA). The aim of this study was to investigate the... 
prediction of response | tapering | biologic agents | rheumatoid arthritis | biomarkers | calprotectin | Studies | Tumor necrosis factor-TNF | Systematic review | Health risk assessment
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.